Cel Sci Corporation (CVM)

[Fosco1]

Henkel

Appologies. I had read too quickly the initial publication. Thought significance was there for the whole population. That was my reading and I was in shock when I understood I was wrong.

Unfortunately cup is half empty. My initial reading was wrong, significance is here but only for a subgroup, those who do not go under chemo

That's half of the target population if I am not wrong : overall, there is no reason the drug not to be approved, but the market will have to weight this as overall primary endpoint was not reached. The results are interesting and should be sufficient in my opinion (no need for further study) to allow approval.

This should end positive, one year time from here we will be laughing, first time immunotherapy works prior surgery on non metastatic patients

Market need to digest the half victory